All articles tagged with #endometrial cancer
Originally Published 3 months ago — by yahoo.com
New research indicates that microplastic particles are present in all examined endometrial tissues and are significantly higher in cancerous tissues, potentially disrupting metabolic pathways and contributing to the development of endometrial cancer, raising concerns about the broader impact of plastic pollution on women's reproductive health.
Originally Published 3 months ago — by Times of India
A new study links metabolically active visceral fat around internal organs to more aggressive endometrial cancer in women, suggesting that the activity level of belly fat, not just its amount, influences cancer severity and could lead to new diagnostic and treatment strategies.
Originally Published 5 months ago — by Prevention
Endometrial cancer often presents with subtle signs such as unusual vaginal bleeding, abnormal discharge, constant pelvic pain, changes in bathroom habits, and unexplained weight loss. Recognizing these symptoms early and consulting a doctor is crucial for timely diagnosis and treatment, especially since there is no screening test for this cancer.
Originally Published 6 months ago — by WRAL.com
Wendy Maultsby, diagnosed with endometrial cancer at 32, highlights the rising trend of younger women being affected by this typically older-age cancer, emphasizing the importance of awareness, early detection, and research, especially among at-risk groups.
Originally Published 2 years ago — by BioMed Central
A study published in BMC Women's Health utilized urine metabolomics to assess the efficacy of fertility-sparing treatment in endometrial cancer (EC) patients. The researchers analyzed urine samples using ultra-performance liquid chromatography mass spectrometry (UPLC-MS) and identified distinct metabolites and altered metabolic pathways. They developed a panel of biomarkers that demonstrated high predictive ability in identifying patients with complete remission (CR). The panel consisted of Baicalin, 5beta-1,3,7 (11)-Eudesmatrien-8-one, Indolylacryloylglycine, Edulitine, and Physapubenolide. This non-invasive approach offers a less invasive means of monitoring treatment efficacy and may aid in evaluating fertility-sparing treatments for EC patients. Further research is needed to validate the biomarker panel in larger populations.
Originally Published 2 years ago — by Endpoints News
GSK's checkpoint inhibitor, Jemperli, when added to chemotherapy, has been found to prolong the survival of patients with advanced or recurrent endometrial cancer in a Phase III study. The study met its primary overall survival endpoint, with patients receiving Jemperli-chemo treatment living longer than those in the comparator arm.
Originally Published 2 years ago — by NBC News
Two studies published in the New England Journal of Medicine found that adding immunotherapy drug pembrolizumab to the standard chemotherapy regimen of carboplatin and paclitaxel reduced the risk that patients' advanced or recurrent endometrial cancer would return by up to 70%. The impact was more dramatic in women with a mismatch repair-deficient tumor, a specific type of endometrial cancer. The Food and Drug Administration would need to amend its guidance on using immunotherapy in this way before it's widely implemented as the protocol for treating late-stage endometrial cancer.